【原美源伯根】Cencora（COR）2026财年第一季度业绩报告「NYSE」（英文版）（18页）.pdf

1、Cencora Reports Fiscal 2026 First Quarter Results2026-02-04Revenue of$85.9 billion for the First Quarter,a 5.5%Increase Year-Over-YearFirst Quarter GAAP Diluted EPS of$2.87 and Adjusted Diluted EPS of$4.08Adjusted Operating Income Guidance Raised to Growth of 11.5%to 13.5%Adjusted Diluted EPS Guidan

2、ce Range Reaffirmed at$17.45 to$17.75 for Fiscal 2026Company Completes Acquisition of OneOncologyCONSHOHOCKEN,Pa.-(BUSINESS WIRE)-Cencora,Inc.(NYSE:COR)reported that in its fiscal year 2026 first quarter endedDecember 31,2025,revenue increased 5.5 percent year-over-year to$85.9 billion.On the basis

3、of U.S.generally acceptedaccounting principles(GAAP),diluted earnings per share(EPS)was$2.87 for the first quarter of fiscal 2026 compared to$2.50 in theprior year first quarter.Adjusted diluted EPS,which is a non-GAAP financial measure that excludes items described below,increased9.4 percent to$4.0

4、8 in the fiscal first quarter from$3.73 in the prior year first quarter.Cencora is updating its outlook for fiscal year 2026.The Company does not provide forward-looking guidance on a GAAP basis asdiscussed below in Fiscal Year 2026 Expectations.Adjusted operating income guidance has been raised fro

5、m the previous range ofgrowth of 8%to 10%to growth of 11.5%to 13.5%primarily to reflect the completion of the acquisition of OneOncology and theperformance of the U.S.Healthcare Solutions segment.“Cencora began fiscal 2026 by delivering strong financial performance and advancing our strategy through

6、 the acquisition ofOneOncology,”said Robert P.Mauch,President and Chief Executive Officer of Cencora.“Our ownership of OneOncology cements our specialty MSO footprint and deepens our partnership with physicians leading incancer care,”Mauch continued“As we continue to advance our leadership in specia